Studies from R. Maha et al add new findings in the area of thyroid cancer
2009 AUG 3 - (NewsRx.com) -- "The receptors for thyroid hormone (THR) and oestrogen (ESR) are prototypes of nuclear transcription factors that regulate the expression of target genes. Genetic alterations in the genes of these receptors were found to be involved in cancer development," scientists writing in the Journal of Receptors and Signal Transduction report. "In this study we investigated the association of one SNP (rs2228480, T594T) and one microsatellite marker (D6S440) within the ESR1 gene and a dinucleotide repeat (D17S2189) within the THRA gene, with thyroid cancer risk. A case-control association study was conducted with 299 healthy individuals and 106 patients with thyroid cancer. Genotypic and allelic frequencies for the dinucleotide repeat in the ESR1 gene were similar between thyroid cancer patients and controls. For the AC repeat in the THRA gene, a slightly significant difference was found for the genotype 18/20 between the two groups (P=0.034), which suggests that alleles with less than 20 repeats might have a protective effect in thyroid cancer risk. For the SNP T594T, the A allele was much more prevalent in patients than in controls and was highly associated with the risk of thyroid cancer (OR: 4,56; IC: 3.23-6.44; P< 10(-18)) and seems to have an additive mode of action," wrote R. Maha and colleagues. The researchers concluded: "Our data suggest that the SNP T594T but not the D6S440 and D17S189 is associated with thyroid cancer risk.." Maha and colleagues published their study in the Journal of Receptors and Signal Transduction (Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. Journal of Receptors and Signal Transduction, 2009;29(2):113-118). Additional information can be obtained by contacting A. Rebai, Center Biotechnology Sfax, Unit Bioinformat Biostatistics & Signalling, POB 1177, Sfax 3018, Tunisia. The publisher of the Journal of Receptors and Signal Transduction can be contacted at: Taylor & Francis Inc., 325 Chestnut St., Suite 800, Philadelphia, PA 19106, USA. Keywords: Tunisia, Sfax, Hormones, Oncology, Thyroid Cancer, Thyroid Neoplasms. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
